SEARCH:   Advanced

Blood, 15 March 2008, Vol. 111, No. 6, pp. 3155-3162. Prepublished online as a Blood First Edition Paper on January 11, 2008; DOI 10.1182/blood-2007-09-110312. This Article Full Text Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2007-09-110312v1 111/6/3155    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Alici, E. Articles by Dilber, M. S. Search for Related Content PubMed PubMed Citation Articles by Alici, E. Articles by Dilber, M. S. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components Evren Alici1,2, Tolga Sutlu1, Bo Björkstrand1, Mari Gilljam1, Birgitta Stellan1, Hareth Nahi1, Hernan Concha Quezada1,2, Gösta Gahrton1, Hans-Gustaf Ljunggren2, and M. Sirac Dilber1 1 Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm; and 2 Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden Multiple myeloma (MM) is an incurable plasma cell malignancy with poor outcome. The most promising therapeutic options currently available are combinations of transplantation, targeted pharmacotherapy, and immunotherapy. Cell-based immunotherapy after hematopoietic stem-cell transplantation has been attempted, but with limited efficacy. Natural killer (NK) cells are interesting candidates for new means of immunotherapy; however, their potential clinical use in MM has not been extensively studied. Here, we explored the possibility of expanding NK cells from the peripheral blood of 7 newly diagnosed, untreated MM patients, using good manufacturing practice (GMP)–compliant components. After 20 days of culture, the number of NK cells from these patients had expanded on average 1600-fold. Moreover, expanded NK cells showed significant cytotoxicity against primary autologous MM cells, yet retained their tolerance against nonmalignant cells. Based on these findings, we propose that autologous NK cells expanded ex vivo deserve further attention as a possible new treatment modality for MM. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Altvater, S. Landmeier, S. Pscherer, J. Temme, K. Schweer, S. Kailayangiri, D. Campana, H. Juergens, M. Pule, and C. Rossig 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells Clin. Cancer Res., August 1, 2009; 15(15): 4857 - 4866. [Abstract] [Full Text] [PDF] H. Fujisaki, H. Kakuda, N. Shimasaki, C. Imai, J. Ma, T. Lockey, P. Eldridge, W. H. Leung, and D. Campana Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy Cancer Res., May 1, 2009; 69(9): 4010 - 4017. [Abstract] [Full Text] [PDF] G. Gahrton and B. Bjorkstrand Allogeneic transplantation in multiple myeloma Haematologica, September 1, 2008; 93(9): 1295 - 1300. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020